EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-12.44%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.27B
AUM Growth
+$3.27B
(-17%)
Cap. Flow
-$78.2M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
61.39%
Holding
63
New
6
Increased
5
Reduced
5
Closed
8
Top Buys
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$88.5M |
| 2 |
Janux Therapeutics
JANX
|
$61.6M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
$24.1M |
| 4 |
iTeos Therapeutics
ITOS
|
$18.6M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$18.4M |
Top Sells
| 1 |
Atara Biotherapeutics
ATRA
|
$83M |
| 2 |
Sarepta Therapeutics
SRPT
|
$81M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$75.5M |
| 4 |
Alector
ALEC
|
$24.4M |
| 5 |
Nkarta
NKTX
|
$21.6M |
Sector Composition
| 1 | Healthcare | 99.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $445M | 13.62% | 11,607,425 +250,000 | +2% | +$9.59M |
|
2
Prothena Corp
PRTA
$441M
| $239M | 7.31% | 11,584,280 | – | – |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $222M | 6.8% | 1,407,322 -512,513 | -27% | -$81M |
|
4
AnaptysBio
ANAB
$569M
| $188M | 5.77% | 7,521,024 | – | – |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $186M | 5.69% | 4,155,375 | – | – |
|
6
Arvinas
ARVN
$568M
| $179M | 5.48% | 6,726,491 | – | – |
|
|
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $170M | 5.19% | 4,982,945 +2,598,561 | +109% | +$88.5M |
|
8
Galapagos
GLPG
$2.07B
| $143M | 4.36% | 5,756,268 | – | – |
|
9
Kura Oncology
KURA
$686M
| $120M | 3.66% | 5,806,871 | – | – |
|
10
Tango Therapeutics
TNGX
$747M
| $114M | 3.5% | 13,330,736 | – | – |
|
11
Zymeworks
ZYME
$1.12B
| $114M | 3.5% | 13,437,473 | – | – |
|
12
Jazz Pharmaceuticals
JAZZ
$7.75B
| $108M | 3.31% | 1,013,952 | – | – |
|
13
Xencor
XNCR
$580M
| $101M | 3.09% | 5,330,416 | – | – |
|
14
CRISPR Therapeutics
CRSP
$4.71B
| $75M | 2.3% | 1,389,276 | – | – |
|
|
15
Janux Therapeutics
JANX
$1.37B
| $61.6M | 1.88% | +1,469,818 | New | +$61.6M |
|
16
Nuvation Bio
NUVB
$1.02B
| $56.1M | 1.72% | 19,209,643 | – | – |
|
|
CNTA
17
Centessa Pharmaceuticals
CNTA
$2.25B
| $51.6M | 1.58% | 5,714,404 +95,625 | +2% | +$863K |
|
|
18
iTeos Therapeutics
ITOS
| $48.2M | 1.48% | 3,249,835 +1,250,586 | +63% | +$18.6M |
|
19
Immunome
IMNM
$828M
| $46.9M | 1.44% | 3,879,415 | – | – |
|
20
Neurogene
NGNE
$264M
| $46.3M | 1.42% | 1,271,342 | – | – |
|
|
THRD
21
DELISTED
Third Harmonic Bio
THRD
| $41.4M | 1.27% | 3,182,444 | – | – |
|
22
Mersana Therapeutics
MRSN
$36.5M
| $38.9M | 1.19% | 19,364,688 | – | – |
|
23
Voyager Therapeutics
VYGR
$186M
| $31M | 0.95% | 3,917,546 | – | – |
|
24
Avidity Biosciences
RNA
$5.99B
| $30.9M | 0.95% | 757,576 | – | – |
|
25
TScan Therapeutics
TCRX
$102M
| $29.3M | 0.89% | 5,000,000 | – | – |
|